Targeting DNA repair pathways to overcome cancer drug resistance

References

[1] Hanahan D.The hallmarks of cancer.Cell2000;100:57-70

[2] Hanahan D.Hallmarks of cancer: the next generation.Cell2011;144:646-74

[3] Mirza MR,Ledermann JA.Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.Ann Oncol2018;29:1366-76

[4] Schettini F,Bernocchi O.Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.Eur J Cancer2021;149:134-52

[5] Tutt ANJ,Kaufman B.OlympiA Clinical Trial Steering Committee and InvestigatorsAdjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.N Engl J Med2021;384:2394-405

[6] Carreira S,Arce-Gallego S.Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial.Cancer Discov2021;

[7] Mateo J,Bianchini D.Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol2020;21:162-74 PMCID:PMC6941219

[8] Maughan BL.Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.Expert Opin Pharmacother2021;1-8

[9] Cleary JM,Dougan SK.Opportunities for utilization of DNA repair inhibitors in homologous recombination repair-deficient and proficient pancreatic adenocarcinoma.Clin Cancer Res2021;

[10] Nickoloff JA,Sharma N.Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy.Cancer Drug Resist2021;4:244-63 PMCID:PMC8323830

[11] Gutierrez R.DNA direct reversal repair and alkylating agent drug resistance.Cancer Drug Resist2021;4:414-23

[12] Saliba AN,Kaufmann SH.Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia.Cancer Drug Resist2021;4:125-42 PMCID:PMC8011583

[13] Lee KJ,Bryant H,Schuler M.EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer.Cancer Drug Resist2020;3:980-91

[14] Zeng L,Cooper TS,Yang ES.Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma.Mol Cancer Ther2017;16:591-600 PMCID:PMC5560482

[15] Yang ES,Mehmet A.A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma.Radiother Oncol2021;157:203-9

[16] Juhlin CC.Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?.Cancer Drug Resist2020;3:992-1000

[17] Fabbrizi MR.Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatment.Cancer Drug Resist2020;3:775-790

[18] Liu YL,Zhou Q.BRCA mutations, homologous DNA repair deficiency, tumor mutational burden, and response to immune checkpoint inhibition in recurrent ovarian cancer.JCO Precis Oncol2020;4:665-79 PMCID:PMC7446408

[19] Morand S,Walter A,Nemunaitis J.BRCA1/2 mutation status impact on autophagy and immune response: unheralded target.JNCI Cancer Spectr2020;4:pkaa077 PMCID:PMC7771003

[20] Peyraud F.Combined PARP inhibition and immune checkpoint therapy in solid tumors.Cancers (Basel)2020;12:1502 PMCID:PMC7352466